This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2010 Sep;7(9).

doi: 10.1038/nrclinonc.2010.31-c1.

Lenalidomide for bortezomib-resistant multiple myeloma

Chiara Briani, Tamara Berno, Marta Campagnolo, Renato Zambello

PMID: 20824906
DOI: 10.1038/nrclinonc.2010.31-c1

Comment

Lenalidomide for bortezomib-resistant multiple myeloma

Chiara Briani et al. Nat Rev Clin Oncol. 2010 Sep.

. 2010 Sep;7(9).

doi: 10.1038/nrclinonc.2010.31-c1.

Authors

Chiara Briani, Tamara Berno, Marta Campagnolo, Renato Zambello

PMID: 20824906
DOI: 10.1038/nrclinonc.2010.31-c1

No abstract available

PubMed Disclaimer

Comment on

Renal recovery with lenalidomide in a patient with bortezomib-resistant multiple myeloma.
Ludwig H, Zojer N. Ludwig H, et al. Nat Rev Clin Oncol. 2010 May;7(5):289-94. doi: 10.1038/nrclinonc.2010.31. Epub 2010 Mar 30. Nat Rev Clin Oncol. 2010. PMID: 20351701

Similar articles

Lenalidomide efficacy in bortezomib-resistant myeloma.
Gozzetti A, Crupi R, Defina M, Bocchia M. Gozzetti A, et al. Nat Rev Clin Oncol. 2010 Sep;7(9). doi: 10.1038/nrclinonc.2010.31-c2. Nat Rev Clin Oncol. 2010. PMID: 20824907 No abstract available.
Drugs: More shots on target.
Appel A. Appel A. Nature. 2011 Dec 14;480(7377):S40-2. doi: 10.1038/480S40a. Nature. 2011. PMID: 22169800 No abstract available.
Bortezomib in multiple myeloma.
Meisler AI. Meisler AI. N Engl J Med. 2003 Sep 25;349(13):1287-8; author reply 1287-8. N Engl J Med. 2003. PMID: 14510013 No abstract available.
Clinical update: novel targets in multiple myeloma.
Anderson KC. Anderson KC. Semin Oncol. 2004 Dec;31(6 Suppl 16):27-32; discussion 33. doi: 10.1053/j.seminoncol.2004.10.016. Semin Oncol. 2004. PMID: 15799242 Review.
Diagnosis and the current trends in multiple myeloma therapy.
Dmoszyńska A. Dmoszyńska A. Pol Arch Med Wewn. 2008 Oct;118(10):563-6. Pol Arch Med Wewn. 2008. PMID: 19112817 Review.

See all similar articles

Cited by

Peripheral neuropathies in chronic lymphocytic leukemia: a single center experience on 816 patients.
Briani C, Visentin A, Salvalaggio A, Imbergamo S, Piazza F, Cacciavillani M, Campagnolo M, Frezzato F, Semenzato G, Trentin L. Briani C, et al. Haematologica. 2017 Apr;102(4):e140-e143. doi: 10.3324/haematol.2016.153064. Epub 2016 Dec 7. Haematologica. 2017. PMID: 27927770 Free PMC article. No abstract available.
Downregulation of MicroRNA-152 contributes to high expression of DKK1 in multiple myeloma.
Xu Y, Chen B, George SK, Liu B. Xu Y, et al. RNA Biol. 2015;12(12):1314-22. doi: 10.1080/15476286.2015.1094600. RNA Biol. 2015. PMID: 26400224 Free PMC article.

References

1. Nat Rev Clin Oncol. 2010 May;7(5):289-94 - PubMed
1. Cancer. 2007 Sep 1;110(5):1042-9 - PubMed
1. J Peripher Nerv Syst. 2007 Sep;12(3):210-5 - PubMed
1. Neurology. 2009 Sep 8;73(10):812-3 - PubMed
1. Expert Opin Pharmacother. 2009 Jan;10(1):125-33 - PubMed

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Nature Publishing Group
Medical
- MedlinePlus Health Information